659,730 Shares in Omeros Corporation $OMER Bought by Corient Private Wealth LP

Corient Private Wealth LP purchased a new stake in Omeros Corporation (NASDAQ:OMER) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm purchased 659,730 shares of the biopharmaceutical company’s stock, valued at approximately $6,274,000. Corient Private Wealth LP owned about 0.91% of Omeros as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. International Assets Investment Management LLC grew its stake in shares of Omeros by 16.0% during the first quarter. International Assets Investment Management LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $61,000 after acquiring an additional 800 shares during the last quarter. Farther Finance Advisors LLC boosted its stake in Omeros by 16.5% in the 4th quarter. Farther Finance Advisors LLC now owns 7,106 shares of the biopharmaceutical company’s stock worth $122,000 after purchasing an additional 1,004 shares in the last quarter. State of Wyoming acquired a new stake in Omeros in the 4th quarter worth approximately $25,000. AQR Capital Management LLC grew its position in Omeros by 7.2% during the 4th quarter. AQR Capital Management LLC now owns 22,838 shares of the biopharmaceutical company’s stock worth $392,000 after purchasing an additional 1,532 shares during the last quarter. Finally, ProShare Advisors LLC grew its position in Omeros by 12.1% during the 4th quarter. ProShare Advisors LLC now owns 15,171 shares of the biopharmaceutical company’s stock worth $261,000 after purchasing an additional 1,637 shares during the last quarter. Institutional investors and hedge funds own 48.79% of the company’s stock.

Omeros Stock Performance

OMER opened at $18.61 on Monday. Omeros Corporation has a 12-month low of $3.94 and a 12-month high of $19.65. The firm has a market capitalization of $1.35 billion, a PE ratio of 14.54 and a beta of 2.54. The firm has a 50 day moving average of $12.64 and a two-hundred day moving average of $12.03.

Omeros (NASDAQ:OMER) last released its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.27) by $0.29. The business had revenue of $28.53 million during the quarter, compared to analysts’ expectations of $12.69 million. As a group, analysts predict that Omeros Corporation will post -0.37 EPS for the current fiscal year.

Insider Buying and Selling at Omeros

In other news, CAO David J. Borges sold 10,000 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $18.95, for a total value of $189,500.00. Following the sale, the chief accounting officer owned 5,906 shares in the company, valued at $111,918.70. This represents a 62.87% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Arnold C. Hanish sold 10,000 shares of the firm’s stock in a transaction dated Thursday, August 27th. The stock was sold at an average price of $18.95, for a total value of $189,500.00. Following the sale, the director directly owned 5,000 shares in the company, valued at approximately $94,750. This trade represents a 66.67% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders have sold 45,906 shares of company stock valued at $850,455. 10.50% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on OMER shares. Weiss Ratings raised shares of Omeros from a “sell (d+)” rating to a “hold (c-)” rating in a report on Wednesday, August 5th. Wall Street Zen raised shares of Omeros from a “hold” rating to a “buy” rating in a report on Saturday, August 15th. Zacks Research downgraded Omeros from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 13th. Finally, HC Wainwright restated a “buy” rating on shares of Omeros in a research note on Monday, July 27th. One equities research analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating and three have given a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $38.00.

Omeros Profile

Omeros Corporation is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of small-molecule and protein therapeutics. The company’s research programs target inflammation, complement-mediated diseases and disorders of the central nervous system. Omeros’s portfolio encompasses both internally discovered molecules and biologics, reflecting its commitment to advancing treatments for conditions with high unmet medical need.

Omeros’s first FDA-approved product, Omidria® (phenylephrine and ketorolac intraocular solution), is indicated to maintain pupil size by preventing intraoperative miosis and reducing postoperative pain in patients undergoing cataract surgery.